This trial was designed to study whether EMP had better effect than DES as the primary treatment of high-grade, disseminated prostate cancer. The results did not confirm this hypothesis. On the contrary, treatment with DES had relatively good effect on this very aggressive form of prostate ...
A Gleason grade predicts how fast cancer might spread on a scale of 1—5. One biopsy sample may have two Gleason grades, which are added together to provide a Gleason score. The higher a Gleason score, the more likely the cancer is to spread.2 Patients at high risk for the development...
centers for patients with high-risk prostate cancer as defined by NCCN (clinical T category 3 or 4 determined by physical examination, initial PSA [iPSA] level >20 ng/mL, and Gleason grade group 4 or 5) who received definitive treatment with high-dose EBRT or EBRT+BT in 2000 to 2014. ...
“A history of treatment with statins was associated with a 15% reduction in the relative risk of low-grade prostate cancer and a 46% lower risk of developing high-grade disease. However, the association was limited to men who took statins for 11 months or longer and those who took a rel...
(NCCN) notes that a DRE should not be used as a stand-alone test for detection of prostate cancer but should be performed in men with an elevated PSA. The NCCN also notes that DRE may be considered as a baseline test in all patients, as it may help identify high-grade cancers ...
dMark Twain M ANY urologists seem to "know" that radical pros- tatectomy (RP) provides greater survival than radiotherapy (RT), and as a result there has been an increase in the performance of surgery for high risk prostate cancer in the last 5 years. 1 This hypothesis is supported by ...
(NCCN) notes that a DRE should not be used as a stand-alone test for detection of prostate cancer but should be performed in men with an elevated PSA. The NCCN also notes that DRE may be considered as a baseline test in all patients, as it may help identify high-grade cancers ...
A Decision Analysis for Treatment of Clinically Localized Prostate Cancer OBJECTIVE: To determine the preferred treatment of clinically localized prostate cancer. DESIGN: Cancer grade, patient age, and comorbidities are considere... MW Kattan,ME Cowen,BJ Miles - 《Journal of General Internal Medicine...
PCA-3 Test:PCA-3 is a cancer marker, specific for prostate cancer. In some cases, this newer test may allow the patient to avoid having a prostate biopsy. This test is ordered when PSA is high or the patient has a high risk of prostate cancer. It is a urine test, performed by vigo...
(NCCN) notes that a DRE should not be used as a stand-alone test for detection of prostate cancer but should be performed in men with an elevated PSA. The NCCN also notes that DRE may be considered as a baseline test in all patients, as it may help identify high-grade cancers ...